PMMA vs Polysulfone in SARS-CoV-2 Infection Hemodialysis Patients (Dial-COVID)

Fundación para la Investigación del Hospital Clínico de Valencia

Status

Unknown

Conditions

SARS-CoV-2 Infection

Treatments

Device: PS membrane versus PMMA membrane,

Study type

Interventional

Funder types

Other

Identifiers

NCT05040737

Dial-COVID

Details and patient eligibility

About

Controlled, prospective, open-label trial with a total duration of 2 weeks to assess the clearance of inflammatory interleukins by different membranes in haemodialysis patients with COVID-19.

Full description

Controlled, prospective, open-label trial with a total duration of 2 weeks to assess the clearance of inflammatory interleukins by different membranes in haemodialysis patients with COVID-19.

Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.

Enrollment

12 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18 years .
Patient on chronic haemodialysis admitted to the hospital with a diagnosis of infection by COVID-19.
Signature of informed consent or legal representative.
Estimated duration of admission greater than 8 days (4 haemodialysis sessions).
Patient with haemodynamic stability, understood as systolic blood pressure ≥ 100 mmHg.

Exclusion criteria

Refusal to sign the consent form.
Patients who for clinical reasons are unable to follow a regular dialysis schedule of three sessions per week.
Allergy (documented or suspected) to either of the two membranes involved in the study.
Patient with haemodynamic instability (Mean arterial pressure < 100 mmHg).